ORAGENICS INC (OGEN) Stock Price, Quote, News and Overview
NYSEARCA:OGEN - NYSE Arca - US6840235005 - Common Stock - Currency: USD
OGEN Quote, Performance and Key Statistics
0.2857
+0 (+1.03%)
The current stock price of OGEN is 0.2857 USD. In the past month the price increased by 0.6%. In the past year, price decreased by -91.29%.
OGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About OGEN
Company Profile
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 5 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Company Info
ORAGENICS INC
1990 Main Street, Suite 750
Sarasota FLORIDA 33634 US
CEO: Alan Joslyn
Employees: 5
Company Website: https://www.oragenics.com/
Investor Relations: http://www.oragenics.com/?q=investors
Phone: 18132867900
ORAGENICS INC / OGEN FAQ
What is the stock price of ORAGENICS INC today?
The current stock price of OGEN is 0.2857 USD. The price increased by 1.03% in the last trading session.
What is the ticker symbol for ORAGENICS INC stock?
The exchange symbol of ORAGENICS INC is OGEN and it is listed on the NYSE Arca exchange.
On which exchange is OGEN stock listed?
OGEN stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for ORAGENICS INC stock?
7 analysts have analysed OGEN and the average price target is 91.8 USD. This implies a price increase of 32031.61% is expected in the next year compared to the current price of 0.2857. Check the ORAGENICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORAGENICS INC worth?
ORAGENICS INC (OGEN) has a market capitalization of 3.49M USD. This makes OGEN a Nano Cap stock.
How many employees does ORAGENICS INC have?
ORAGENICS INC (OGEN) currently has 5 employees.
What are the support and resistance levels for ORAGENICS INC (OGEN) stock?
ORAGENICS INC (OGEN) has a resistance level at 0.42. Check the full technical report for a detailed analysis of OGEN support and resistance levels.
Should I buy ORAGENICS INC (OGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OGEN, evaluating the profitability, health, valuation and growth aspects
- ORAGENICS INC (OGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORAGENICS INC (OGEN) Sales and EPS estimates to see what analysts future expectations are.
- ORAGENICS INC (OGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORAGENICS INC (OGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORAGENICS INC (OGEN) Stock Chart to make your own analysis
- ORAGENICS INC (OGEN) Latest news and press-releases to stay up to date.
Does ORAGENICS INC (OGEN) stock pay dividends?
OGEN does not pay a dividend.
When does ORAGENICS INC (OGEN) report earnings?
ORAGENICS INC (OGEN) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of ORAGENICS INC (OGEN)?
ORAGENICS INC (OGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.51).
What is the Short Interest ratio of ORAGENICS INC (OGEN) stock?
The outstanding short interest for ORAGENICS INC (OGEN) is 22.8% of its float. Check the ownership tab for more information on the OGEN short interest.
OGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OGEN. When comparing the yearly performance of all stocks, OGEN is a bad performer in the overall market: 94.54% of all stocks are doing better.
OGEN Financial Highlights
Over the last trailing twelve months OGEN reported a non-GAAP Earnings per Share(EPS) of -6.51. The EPS decreased by -36.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -383.66% | ||
| ROE | -648.76% | ||
| Debt/Equity | 0.17 |
OGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to OGEN. The Buy consensus is the average rating of analysts ratings from 7 analysts.